Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589547 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
A Phase 2 study of Stage III Non-small Cell Lung Cancer, sponsored by Brown University.
- Active
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT03589547 is a Phase 2 study of Stage III Non-small Cell Lung Cancer that is active but no longer recruiting, run by Brown University. The registered enrollment target is 11 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT03589547, a Phase 2 study of Stage III Non-small Cell Lung Cancer, is active but no longer recruiting, sponsored by Brown University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation. With SBRT, radiation is focused toward the cancer and away from normal surrounding lung tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more effective in activating the immune system. SBRT is a standard FDA approved treatment for early stage (stage 1) lung cancer and is investigational in patients such as yourself with stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.
Conditions Studied
Interventions
- RADIATION SBRT
- DRUG Durvalumab
Study Locations (2)
Rhode Island
- Rhode Island Hospital - Providence
- The Miriam Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589547
The ClinicalTrials.gov registry entry for NCT03589547 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage III Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which SBRT is the first listed.
NCT03589547 reports 2 study locations spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT03589547 about?
NCT03589547 is a clinical study titled "Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung". Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation. With SBRT, radiation is fo...
What is the current status of trial NCT03589547?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2019-05-13. Estimated completion is 2026-10.
What conditions does trial NCT03589547 study?
This clinical trial studies the following conditions: Stage III Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT03589547?
The interventions under investigation include: SBRT (RADIATION), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03589547?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03589547 being conducted?
This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.